Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Mavrilimumab, a human monoclonal antibody targeting the alpha subunit of the granulocyte-macrophage colony-stimulating factor receptor, was evaluated in a phase 2 randomised, double-blind, placebo-controlled study to investigate efficacy and safety in subjects with rheumatoid arthritis (RA). METHODS: Subcutaneous mavrilimumab (10 mg, 30 mg, 50 mg, or 100 mg) or placebo was administered every other week for 12 weeks in subjects on stable background methotrexate therapy. The primary endpoint was the proportion of subjects achieving a ≥1.2 decrease from baseline in Disease Activity Score (DAS28-CRP) at week 12. RESULTS: 55.7% of mavrilimumab-treated subjects met the primary endpoint versus 34.7% placebo (p=0.003) at week 12; for the 10 mg, 30 mg, 50 mg, and 100 mg groups, responses were 41.0% (p=0.543), 61.0% (p=0.011), 53.8% (p=0.071), and 66.7% (p=0.001) respectively. Response rate differences from placebo were observed at week 2 and increased throughout the treatment period. The 100 mg dose demonstrated a significant effect versus placebo on DAS28-CRP<2.6 (23.1% vs 6.7%, p=0.016), all categories of the American College of Rheumatology (ACR) criteria (ACR20: 69.2% vs 40.0%, p=0.005; ACR50: 30.8% vs 12.0%, p=0.021; ACR70: 17.9% vs 4.0%, p=0.030), and the Health Assessment Questionnaire Disability Index (-0.48 vs -0.25, p=0.005). A biomarker-based disease activity score showed a dose-dependent decrease at week 12, indicating suppression of disease-related biological pathways. Adverse events were generally mild or moderate in intensity. No significant hypersensitivity reactions, serious or opportunistic infections, or changes in pulmonary parameters were observed. CONCLUSIONS: Mavrilimumab induced rapid clinically significant responses in RA subjects, suggesting that inhibiting the mononuclear phagocyte pathway may provide a novel therapeutic approach for RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
The Pathogenesis of Rheumatoid Arthritis
McInnes, I. B., & Schett, G. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004965 · Cited by 5,514
Self-citationCodarri, L., Gyülvészi, G., Tosevski, V., Hesske, L., Fontana, A., Magnenat, L., Suter, T., & Becher, B. (2011) · Nature Immunology · doi:10.1038/ni.2027 · Cited by 1,191
El-Behi, M., Ciric, B., Dai, H., Yan, Y., Cullimore, M., Safavi, F., Zhang, G.-X., Dittel, B. N., & Rostami, A. (2011) · Nature Immunology · doi:10.1038/ni.2031 · Cited by 1,071
Cited by
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
Lin, Y.-J., Anzaghe, M., & Schülke, S. (2020) · Cells · doi:10.3390/cells9040880 · Cited by 932
Macrophage heterogeneity in the context of rheumatoid arthritis
Udalova, I. A., Mantovani, A., & Feldmann, M. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.91 · Cited by 686
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Schwartz, D. M., Bonelli, M., Gadina, M., & O'Shea, J. J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.167 · Cited by 648
The pathogenicity of Th17 cells in autoimmune diseases
Yasuda, K., Takeuchi, Y., & Hirota, K. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00733-8 · Cited by 555
Cytokines in rheumatoid arthritis — shaping the immunological landscape
McInnes, I. B., Buckley, C. D., & Isaacs, J. D. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.171 · Cited by 504
Self-citation
Metadata
- Authors
- Burmester, G. R., Weinblatt, M. E., McInnes, I. B., Porter, D., Barbarash, O., Vatutin, M., Szombati, I., Esfandiari, E., Sleeman, M. A., Kane, C. D., Cavet, G., Wang, B., Godwood, A., & Magrini, F.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2013-09
- Volume
- 72
- Issue
- 9
- Pages
- 1445-1452
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2147975139
- Cited by
- 157
- References
- 4
- FWCI
- 12.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. https://app.cochat.ai/papers/10.1136/annrheumdis-2012-202450
- The paper
- Burmester, G. R., Weinblatt, M. E., McInnes, I. B., Porter, D., Barbarash, O., Vatutin, M., Szombati, I., Esfandiari, E., Sleeman, M. A., Kane, C. D., Cavet, G., Wang, B., Godwood, A., & Magrini, F. (2013). Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2012-202450
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.